US 7198788
Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26.
granted A61KA61K2039/505A61K38/19
Quick answer
US patent 7198788 (Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26.) held by The Board of Regents of the University of Texas System expires Mon Mar 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Apr 03 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 35
- CPC classes
- A61K, A61K2039/505, A61K38/19, A61P, A61P1/00